Scientific topics
Keywords
Kadiombo Bantubungi PhD in Biomedical Sciences
Course and current status
Kadiombo BANTUBUNGI
Born July 26th 1975 in Brussels
Belgian Citizen
Married, 1 child
Current position
Assistant Professor (Permanent Staff)
Inserm U1011
“Nuclear Receptor, Cardio-vascular diseases and Diabetes”
Director: Dr. Bart Staels
1, rue du Professeur Calmette
F-59019 Lille cedex, France
Tel: +33320974209
Fax: +33320974201
Education
Undergraduate studies (Université Libre de Bruxelles-ULB, Brussels, Belgium)
1995-1999: « Candidatures » and « Licences » of Biomedical Sciences
Graduate studies
2000-2001: Master Degree in Health Sciences, ULB, Brussels, Belgium
2001-2006: PhD in Biomedical Sciences in Neurophysiology Lab (Prs. Vanderhaeghen and Schiffmann), ULB, Brussels, Belgium
Post-doctoral fellows
2006-2008: U837, Jean-Pierre Aubert Research Centre, Team “Development and Plasticity of post-natal brain” (Dr. Prévot), Lille, France
2008-2010: Inserm U1011, “Nuclear Receptor, Cardio-vascular diseases and Diabetes” (Dr. Staels), Lille, France
Other
2007: Habilitation for animal experiments
Research experience
2001-2006: PhD in Biomedical Sciences in Neurophysiology Lab (Director: Schiffmann), ULB, Brussels, Belgium. “Pharmacological therapy and characterization of intracerebral migration mechanisms of stem cells in neurodegenerative diseases: application to Huntington‘s disease”.
2006-2008: U837, Jean-Pierre Aubert Research Centre, Team “Development and Plasticity of post-natal brain” (Dr. Prévot), Lille, France. “Leptin transport through median eminence of hypothalamus”.
2008-2010: Inserm U1011, “Nuclear Receptor, Cardio-vascular diseases and Diabetes” (Dr.Staels), Lille, France. “ Nuclear receptors and cardio-metabolic diseases”.
Fields of interest
Pathophysiology of metabolic diseases
Relationship between metabolism and HPA axis
Nuclear Receptors
Experimental models
Neuroendocrine control of metabolism
Translational research
Scientific summary
Our unit study the biological and molecular mechanisms controlling the development of artherosclerosis in order to develop preventive and therapeutic strategies against its cardiovascular complications, and study metabolic risk factors, such as dyslipidemia and type 2 diabetes. We are focusing on the regulation of genes involved in these pathologies and on the consequences of their dysregulation, studying the molecular basis and the pathophysiological involvement of nuclear receptors, transcription factors which our unit has been studying for several years.
